{"id":3338,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1992-01-22","marketCap":82848.640625,"name":"Gilead Sciences Inc","phone":"16505743000","outstanding":1246.969970703125,"symbol":"GILD","website":"https://www.gilead.com/","industry":"Biotechnology"},"price":66.52125,"year":2024,"month":4,"day":19,"weekday":"Friday","title":"Market Cycles and Their Influence on Gilead Sciences Inc Stock Prices","date":"2024-04-19","url":"/posts/2024/04/19/GILD","content":[{"section":"Introduction","text":"Market cycles refer to the recurring patterns and fluctuations in the financial markets. These cycles are influenced by various factors such as economic conditions, investor sentiment, industry trends, and company-specific factors. Understanding market cycles is crucial for investors to make informed decisions and identify potential opportunities and risks."},{"section":"Market Cycles and Gilead Sciences Inc","text":"Gilead Sciences Inc is a biopharmaceutical company known for its innovative treatments in areas such as HIV/AIDS, liver diseases, and cancer. The stock prices of Gilead Sciences Inc can be influenced by market cycles, as well as the performance of the healthcare and biotechnology sectors."},{"section":"Example 1 - Bull Market Cycle","text":"During a bull market cycle, when the overall market sentiment is optimistic and prices are rising, Gilead Sciences Inc stock prices may also experience an upward trend. This can be due to positive investor sentiment towards the company's research pipeline, successful clinical trial results, and potential revenue growth."},{"section":"Example 2 - Bear Market Cycle","text":"In a bear market cycle, when the market sentiment is pessimistic and prices are declining, Gilead Sciences Inc stock prices may also be negatively impacted. Investors may become more risk-averse and sell their stocks, resulting in price depreciation. Factors such as economic downturns, regulatory challenges, or negative news related to the company's products can contribute to this decline."},{"section":"Example 3 - Sector-Specific Market Cycle","text":"Market cycles can also be influenced by sector-specific trends. For example, if the healthcare or biotechnology sector is experiencing a period of rapid growth and investor interest, Gilead Sciences Inc stock prices may benefit from this positive sector sentiment. Conversely, if the sector faces challenges or regulatory uncertainties, it can negatively impact the company's stock prices."},{"section":"Conclusion","text":"Market cycles play a significant role in influencing the stock prices of Gilead Sciences Inc. Understanding these cycles and their potential impact on the company is essential for investors. By monitoring market trends, economic indicators, and sector-specific factors, investors can gain insights into the potential future performance of Gilead Sciences Inc stock."}],"tags":["OverSold","Long","Biotechnology"],"news":[{"category":"company","date":1713462300,"headline":"Gilead Sciences Publishes 2023 ESG Impact Report","id":127084520,"image":"https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613","symbol":"GILD","publisher":"Yahoo","summary":"NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...","url":"https://finance.yahoo.com/news/gilead-sciences-publishes-2023-esg-174500646.html"},{"category":"company","date":1713448899,"headline":"Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for","id":127081284,"image":"https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/analysts-estimate-gilead-sciences-gild-140139125.html"},{"category":"company","date":1713448769,"headline":"Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value","id":127081093,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Caribou Biosciences, Inc. expects promising phase 1 studies on CB-010 and CB-011 for various lymphoma and myeloma treatments by Q2 2024. Click for my CRBU update.","url":"https://seekingalpha.com/article/4684523-caribou-biosciences-two-clinical-data-updates-in-2024-could-bring-value"},{"category":"company","date":1713446778,"headline":"ALX Oncology: Trying To Justify The Hype","id":127080348,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/81860632/image_81860632.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"ALX Oncology'sÂ has a strong financial position withÂ evorpacept, which has shown encouraging results for various cancer therapies. See more on ALXO stock here.","url":"https://seekingalpha.com/article/4684509-alx-oncology-trying-to-justify-the-hype"},{"category":"company","date":1713442800,"headline":"What the Options Market Tells Us About Gilead Sciences","id":127090882,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450500544"},{"category":"company","date":1713433380,"headline":"Stifel starts Mirum at buy, cites IBATi drug potential","id":127088851,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450285749"},{"category":"company","date":1713416820,"headline":"Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns","id":127083829,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3449974241"},{"category":"company","date":1713337200,"headline":"ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary","id":127051576,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690117/image_1340690117.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"U.S. equities continued their upward march in the first quarter as the momentum rally, begun following Novemberâs inflation print, showed few signs of flagging.","url":"https://seekingalpha.com/article/4684199-clearbridge-sustainability-leaders-strategy-q1-2024-portfolio-manager-commentary"},{"category":"company","date":1713333780,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA","id":127052585,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\") in Lisbon.","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-060300915.html"},{"category":"company","date":1713325680,"headline":"Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors","id":127090886,"image":"","symbol":"GILD","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448998553"},{"category":"company","date":1713317700,"headline":"If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today","id":127059851,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448805041"},{"category":"company","date":1713273240,"headline":"Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why","id":127031058,"image":"https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad","symbol":"GILD","publisher":"Yahoo","summary":"Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.","url":"https://finance.yahoo.com/news/xilios-xlo-shares-surge-79-131400846.html"},{"category":"company","date":1713272410,"headline":"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know","id":127032844,"image":"https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f","symbol":"GILD","publisher":"Yahoo","summary":"Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-attracting-130010099.html"},{"category":"company","date":1713258950,"headline":"Pfizer's Doldrums, Just A Bad Case Of COVID-19?","id":127030002,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351419442/image_1351419442.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Pfizer may be worth buying as the COVID-based product revenues decline and equilibrate. Click here to read why I'm bullish on PFE stock.","url":"https://seekingalpha.com/article/4683994-pfizer-doldrums-just-a-bad-case-of-covid-19-pfe-stock"},{"category":"company","date":1713182400,"headline":"Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?","id":127011027,"image":"https://g.foolcdn.com/editorial/images/772686/man-holding-cash-dividends.jpg","symbol":"GILD","publisher":"Yahoo","summary":"Dividend stocks can be a smart way to ride out market volatility.","url":"https://www.fool.com/investing/2024/04/15/should-you-buy-the-3-highest-paying-dividend-stock/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1713157560,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA","id":127010171,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit (\"Summit\"). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\"","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-050600305.html"},{"category":"company","date":1713154920,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG","id":127008266,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis C, hepatitis B, and hepatitis D in conjunction with the World Hepatitis Summit (\"Summit\"). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\") in Lisbon from 9","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-042200925.html"},{"category":"company","date":1712959219,"headline":"Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know","id":126990531,"image":"https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b","symbol":"GILD","publisher":"Yahoo","summary":"In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.","url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220019609.html"},{"category":"company","date":1712915280,"headline":"Stocks with the highest swings in option premium price over 3 months - JPM","id":126979403,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3441550054"},{"category":"company","date":1712898708,"headline":"U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map","id":126975802,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Read more to see the April 2024 heat map.","url":"https://seekingalpha.com/article/4683411-us-wide-moat-stocks-on-sale-the-april-2024-heat-map"},{"category":"company","date":1712839980,"headline":"Attractive call buying opportunities for Russell 1000 stocks - JPM","id":126960691,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3440060577"},{"category":"company","date":1712831760,"headline":"GILD May 31st Options Begin Trading","id":126968665,"image":"","symbol":"GILD","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3439872120"},{"category":"company","date":1712821740,"headline":"Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter","id":126959702,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3439658109"},{"category":"company","date":1712811420,"headline":"Gilead Sciences: Robust HIV Business and Oncology Growth Potential Justify Buy Rating","id":126968667,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3439485880"},{"category":"company","date":1712786947,"headline":"12 Best Depressed Stocks To Buy in 2024","id":126946550,"image":"https://s.yimg.com/ny/api/res/1.2/ZxPxwmftfSJzeP73vbNqqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/a46da9068c58072daab2f794893d76d8","symbol":"GILD","publisher":"Yahoo","summary":"In this article, we will take a detailed look at the 12 Best Depressed Stocks To Buy in 2024. For a quick overview of the 5 such stocks, read our article 5 Best Depressed Stocks To Buy in 2024. JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite […]","url":"https://finance.yahoo.com/news/12-best-depressed-stocks-buy-220907044.html"},{"category":"company","date":1712753400,"headline":"ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary","id":126937476,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2108172267/image_2108172267.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"The ClearBridge Value Equity Strategy outperformed its Russell 1000 Value Index during the first quarter of 2024. Click here to read the full fund letter.","url":"https://seekingalpha.com/article/4683145-clearbridge-value-equity-strategy-q1-2024-portfolio-manager-commentary"},{"category":"company","date":1712700919,"headline":"Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider","id":126926962,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.","url":"https://finance.yahoo.com/news/gilead-sciences-gild-exceeds-market-221519478.html"},{"category":"company","date":1712688017,"headline":"3 Stocks at 52-Week Lows Poised for a Powerful Rebound","id":127016013,"image":"https://media.zenfs.com/en/investorplace_417/bec0a9b426e9a19691d0cbf1a1da581f","symbol":"GILD","publisher":"Yahoo","summary":"With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential. While exercising caution is prudent, given valid underperformance reasons exist, comparing current metrics to historical peaks could reveal bargain stocks at 52-week lows. Understanding the drivers of underperformance provides insight into rebound likelihood. Since recovery duration may mirror price","url":"https://finance.yahoo.com/news/3-stocks-52-week-lows-184017645.html"},{"category":"company","date":1712666400,"headline":"10 Health Care Stocks With Whale Alerts In Today's Session","id":126919712,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436536831"},{"category":"company","date":1712662637,"headline":"11 Best Biotech ETFs To Buy","id":126913134,"image":"https://s.yimg.com/ny/api/res/1.2/RCKFyA_Orx5i7EcMSHyUbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/bbad2545b3b325a6c633bba783765287","symbol":"GILD","publisher":"Yahoo","summary":"In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]","url":"https://finance.yahoo.com/news/11-best-biotech-etfs-buy-113717831.html"},{"category":"company","date":1712653680,"headline":"Madrigal announces US launch of NASH/MASH drug Rezdiffra","id":126915308,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436244299"},{"category":"company","date":1712652060,"headline":"Unusually active option classes on open April 9th","id":126915475,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3436208811"},{"category":"company","date":1712606700,"headline":"Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024","id":126908086,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 08, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2024 financial results and provide a business update.","url":"https://finance.yahoo.com/news/gilead-sciences-release-first-quarter-200500175.html"},{"category":"company","date":1712569860,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)","id":126923785,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3435606753"},{"category":"company","date":1712542680,"headline":"Fly Insider: Xilio, Aerovate among weekâ����s notable insider trades","id":126900551,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3434931206"},{"category":"company","date":1712541180,"headline":"Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?","id":126902592,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3434896431"},{"category":"company","date":1712400540,"headline":"3 No-Brainer Dividend Stocks to Buy in April","id":126877067,"image":"https://g.foolcdn.com/editorial/images/771862/hands-behind-head.jpg","symbol":"GILD","publisher":"Yahoo","summary":"Income investors will find a lot to like about these stocks.","url":"https://www.fool.com/investing/2024/04/06/3-no-brainer-dividend-stocks-to-buy-in-april/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1712385900,"headline":"ClearBridge Dividend Strategy Q1 2024 Portfolio Manager Commentary","id":126876577,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"The marketâs rise continues to be led by a small handful of mega cap technology names, with those companies and the IT sector together now accounting for almost 40% of the S\u0026P 500 Index.","url":"https://seekingalpha.com/article/4682491-clearbridge-dividend-strategy-q1-2024-portfolio-manager-commentary"},{"category":"company","date":1712320200,"headline":"Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows","id":126860324,"image":"https://g.foolcdn.com/editorial/images/771254/a-person-counting-money-in-their-living-room.jpg","symbol":"GILD","publisher":"Yahoo","summary":"All of these stocks pay generous dividends that income investors will appreciate.","url":"https://www.fool.com/investing/2024/04/05/got-5000-these-3-high-yielding-dividend-stocks-are/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1712298900,"headline":"GILD Named 'Top Dividend Stock of the Nasdaq 100' at Dividend Channel With 4.4% Yield","id":126863410,"image":"","symbol":"GILD","publisher":"Dividend Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3430839619"}]}